Skip to main content

Advertisement

Log in

Patient educational level and use of newly marketed drugs: a register-based study of over 600,000 older people

  • Pharmacoepidemiology and Prescription
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective

To examine the association between educational level and the use of newly marketed drugs (NMD) among elderly persons.

Methods

We conducted a register-based, retrospective, cross-sectional study of 626,258 people aged 75–89 years who filled at least one drug prescription from August to October 2005 and who, consequently, were registered in the Swedish Prescribed Drug Register (SPDR). Data from the SPDR were record-linked to the Swedish National Inpatient Register and the Education Register. Newly marketed drugs were defined as new chemical entities that had been approved in Sweden between 2000 and 2004.

Results

Overall, NMD were prescribed to 7.3% of the study population. The use of NMD increased with increasing educational level (6.9% for the lowest educated elderly and 8.1% for the highest educated elderly), and education was associated with NMD [odds ratio (OR) 0.82; 95% confidence interval (CI)] 0.80–0.88 for <9 compared with ≥13 years of education) after adjustment for age, sex, type of residential area and number of dispensed drugs. Decreasing educational level was associated with a lower probability of using most of the NMD, especially oseltamivir (adjusted OR 0.16; 95% CI 0.12–0.22 for <9 years of education compared with ≥13 years of education) and ezetimibe.

Conclusions

This study suggests that education-related inequalities in NMD use may exist even in a healthcare system that claims to ensure a high degree of equity. Future research is required to explain why educational level influences the selection of new drugs and whether it has any impact on health outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rosen M (1988) Epidemiological measures in planning: observations from Sweden. Int J Health Plann Manage 3:111–126

    Article  PubMed  CAS  Google Scholar 

  2. Lahelma E, Kivela K, Roos E, Tuominen T, Dahl E, Diderichsen F, Elstad JI, Lissau I, Lundberg O, Rahkonen O, Rasmussen NK, Yngwe MA (2002) Analysing changes of health inequalities in the Nordic welfare states. Soc Sci Med 55:609–625

    Article  PubMed  Google Scholar 

  3. Haider SI, Johnell K, Thorslund M, Fastbom J (2007) Trends in polypharmacy and potential drug-drug interactions across educational groups in elderly patients in Sweden for the period 1992–2002. Int J Clin Pharmacol Ther 45:643–653

    PubMed  CAS  Google Scholar 

  4. Haider SI, Johnell K, Thorslund M, Fastbom J (2008) Analysis of the association between polypharmacy and socioeconomic position among elderly aged ≥ 77 years in Sweden. Clin Ther 30:419–427

    Article  PubMed  Google Scholar 

  5. Merlo J, Lynch JW, Yang M, Lindstrom M, Ostergren PO, Rasmusen NK, Rastam L (2003) Effect of neighborhood social participation on individual use of hormone replacement therapy and antihypertensive medication: a multilevel analysis. Am J Epidemiol 157:774–783

    Article  PubMed  Google Scholar 

  6. Johnell K, Ringback Weitoft G, Fastbom J (2008) Education and use of dementia drugs: a register-based study of over 600,000 older people. Dement Geriatr Cogn Disord 25:54–59

    Article  PubMed  Google Scholar 

  7. Fillenbaum GG, Hanlon JT, Corder EH, Ziqubu-Page T, Wall WE Jr., Brock D (1993) Prescription and nonprescription drug use among black and white community-residing elderly. Am J Public Health 83:1577–1582

    Article  PubMed  CAS  Google Scholar 

  8. Chen YF, Dewey ME, Avery AJ (2001) Self-reported medication use for older people in England and Wales. J Clin Pharm Ther 26:129–140

    Article  PubMed  CAS  Google Scholar 

  9. Dybdahl T, Andersen M, Sondergaard J, Kragstrup J, Kristiansen IS (2004) Does the early adopter of drugs exist? A population-based study of general practitioners’ prescribing of new drugs. Eur J Clin Pharmacol 60:667–672

    Article  PubMed  Google Scholar 

  10. Greving JP, Denig P, van der Veen WJ, Beltman FW, Sturkenboom MC, Haaijer-Ruskamp FM (2006) Determinants for the adoption of angiotensin II receptor blockers by general practitioners. Soc Sci Med 63:2890–2898

    Article  PubMed  Google Scholar 

  11. Coleman J, Menzel H, Katz E (1959) Social processes in Physicians’adoption of a new drug. J Chronic Dis 9:1–19

    Article  PubMed  CAS  Google Scholar 

  12. Tobin L, de Almedia Neto AC, Wutzke S, Patterson C, Mackson J, Weekes L, Williamson M (2008) Influences on the prescribing of new drugs. Aust Fam Physician 37:78–80, 83

    Google Scholar 

  13. Mamdani MM, Tu K, Austin PC, Alter DA (2002) Influence of socioeconomic status on drug selection for the elderly in Canada. Ann Pharmacother 36:804–808

    Article  PubMed  Google Scholar 

  14. Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, Persson I, Sundstrom A, Westerholm B, Rosen M (2007) The new Swedish Prescribed Drug Register-opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 16:726–735

    Article  PubMed  Google Scholar 

  15. Statistics Sweden, Stockholm, Sweden (2004) The Swedish Register of Education. Available at: http://www.scb.se/statistik/UF/UF0506/Produktbeskrivning_short_English_UF0506_20040101r.doc. Accessed 10 Apr 2008

  16. Hardell L, Carlberg M, Hansson Mild K (2005) Use of cellular telephones and brain tumour risk in urban and rural areas. Occup Environ Med 62:390–394

    Article  PubMed  CAS  Google Scholar 

  17. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373–383

    Article  PubMed  CAS  Google Scholar 

  18. Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613–619

    Article  PubMed  CAS  Google Scholar 

  19. Mecocci P, von Strauss E, Cherubini A, Ercolani S, Mariani E, Senin U, Winblad B, Fratiglioni L (2005) Cognitive impairment is the major risk factor for development of geriatric syndromes during hospitalization: results from the GIFA study. Dement Geriatr Cogn Disord 20:262–269

    Article  PubMed  Google Scholar 

  20. Gorecka K, Linhartova A, Vlcek J, Tilser I (2005) Cardiovascular drug utilisation and socio-economic inequalities in 20 districts of the Czech Republic. Eur J Clin Pharmacol 61:417–423

    Article  PubMed  Google Scholar 

  21. Kozyrskyj A, Raymond C, Racher A (2007) Characterizing early prescribers of newly marketed drugs in Canada: a population-based study. Eur J Clin Pharmacol 63:597–604

    Article  PubMed  Google Scholar 

  22. Prosser H, Walley T (2006) New drug prescribing by hospital doctors: the nature and meaning of knowledge. Soc Sci Med 62:1565–1578

    Article  PubMed  Google Scholar 

  23. Prosser H, Walley T (2003) New drug uptake: qualitative comparison of high and low prescribing GPs’ attitudes and approach. Fam Pract 20:583–591

    Article  PubMed  Google Scholar 

  24. Jacoby A, Smith M, Eccles M (2003) A qualitative study to explore influences on general practitioners’ decisions to prescribe new drugs. Br J Gen Pract 53:120–125

    PubMed  Google Scholar 

  25. Steffensen FH, Sorensen HT, Olesen F (1999) Diffusion of new drugs in Danish general practice. Fam Pract 16:407–413

    Article  PubMed  CAS  Google Scholar 

  26. Ohlsson H, Merlo J (2007) Contextual determinants of physicians’ propensity to early adopt and prescribe a new statin (Rosuvastatin)—a multilevel analysis using GEE ALR methodology. In: Nordic Meet Epidemiol Register-based Health Res. Gothenburg, Sweden

  27. Florentinus SR, Nielsen MW, van Dijk L, Leufkens HG, Hansen EH, Heerdink ER (2005) Patient characteristics associated with prescribing of a newly introduced drug: the case of rofecoxib. Eur J Clin Pharmacol 61:157–159

    Article  PubMed  CAS  Google Scholar 

  28. Thomsen RW, Johnsen SP, Olesen AV, Mortensen JT, Boggild H, Olsen J, Sorensen HT (2005) Socioeconomic gradient in use of statins among Danish patients: population-based cross-sectional study. Br J Clin Pharmacol 60:534–542

    Article  PubMed  Google Scholar 

  29. Helin-Salmivaara A, Huupponen R, Virtanen A, Klaukka T (2005) Adoption of celecoxib and rofecoxib: a nationwide database study. J Clin Pharm Ther 30:145–152

    Article  PubMed  CAS  Google Scholar 

  30. Prosser H, Almond S, Walley T (2003) Influences on GPs’ decision to prescribe new drugs-the importance of who says what. Fam Pract 20:61–68

    Article  PubMed  Google Scholar 

  31. Smith KJ, Roberts MS (2002) Cost-effectiveness of newer treatment strategies for influenza. Am J Med 113:300–307

    Article  PubMed  Google Scholar 

  32. Nielsen MW, Gundgaard J, Hansen EH, Rasmussen NK (2005) Use of six main drug therapeutic groups across educational groups: self-reported survey and prescription records. J Clin Pharm Ther 30:259–269

    Article  PubMed  CAS  Google Scholar 

  33. Rouland JF, Le Pen C, Gouveia Pinto C, Berto P, Berdeaux G (2003) Cost-minimisation study of dorzolamide versus brinzolamide in the treatment of ocular hypertension and primary open-angle glaucoma: in four European countries. Pharmacoeconomics 21:201–213

    Article  PubMed  Google Scholar 

  34. Lynch J, Kaplan G (2000) Socioeconomic position. In: Berkman LF, Kawachi I (eds) Social epidemiology. Oxford University Press, New York, pp 13–35

    Google Scholar 

  35. Rosholm JU, Christensen K (1997) Relationship between drug use and self-reported health in elderly Danes. Eur J Clin Pharmacol 53:179–183

    Article  PubMed  CAS  Google Scholar 

  36. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ (2001) Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 154:854–864

    Article  PubMed  CAS  Google Scholar 

Download references

Statement about competing interests

There is no competing interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Syed Imran Haider.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Haider, S.I., Johnell, K., Ringbäck Weitoft, G. et al. Patient educational level and use of newly marketed drugs: a register-based study of over 600,000 older people. Eur J Clin Pharmacol 64, 1215–1222 (2008). https://doi.org/10.1007/s00228-008-0549-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-008-0549-8

Keywords

Navigation